Other News To Note
Tuesday, October 9, 2012
Cellerant Therapeutics Inc., of San Carlos, Calif., said it was awarded a Small Business Innovation Research Phase I contract and a Phase II option from the National Cancer Institute valued up to about $1.7 billion.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.